II. Indications
-
HIV Infection (part of combination therapy)
- FDA approved in 2011 for treatment-naive HIV patients (with HIV RNA <100,000 copies)
- High risk of induced HIV resistance
- Never use NNRTIs as monotherapy in HIV Infection
III. Mechanism
- See Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- Second-generation Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- Rilpivirine is a diarylpyrimidine
IV. Medications
- Oral: 25 mg tablets
- Combination agents
- Cabenuva (Cabotegravir/Rilpivirine) monthly IM Injections
- Juluca (Dolutegravir/Rilpivirine)
V. Dosing: HIV Infection
- For treatment naive patients and HIV RNA <100,000 copies
- Administer in combination with other Antiretrovirals
- Protect medication from light (keep in original packaging)
- Adult (and child age >12 years or weight >35 kg)
- Take 25 mg orally daily with food
VI. Efficacy
VII. Adverse Effects
- See Non-Nucleoside Reverse Transcriptase Inhibitor
-
QTc Prolongation
- Increased risk with high serum levels of Rilpivirine
- Avoid with known QTc Prolongation or other medications that cause Drug-Induced QTc Prolongation
- Hepatotoxicity
- Obtain Liver Function Tests at baseline and periodically (esp. in known liver disease)
VIII. Safety
- Avoid in Lactation
- Pregnancy
- May use in pregnancy if risk outweighs benefit
- Monitor viral loads in pregnancy
- Pregnancy registry exists
IX. Drug Interactions
-
Rifabutin
- Increase Doravirine dose to 50 mg orally daily with food
-
Drug-Induced QTc Prolongation
- Avoid with other agents that prolong QTc
- Metabolized by CYP3A4
- Avoid with strong CYP3A4 Inducers (e.g. Carbamazepine, Phenobarbital, Phenytoin, Rifampin)
-
Antacids
- Antacid Salts (e.g. Aluminum and Magnesium Salt Antacid, Calcium Carbonate)
- Take at least 2 hours before or 4 hours after Rilpivirine
- H2 Blockers
- Take at least 12 hours before or 4 hours after Rilpivirine
- Antacid Salts (e.g. Aluminum and Magnesium Salt Antacid, Calcium Carbonate)
-
Methadone
- Rilpivirine may reduce Methadone effects
X. Resources
Images: Related links to external sites (from Bing)
Related Studies
edurant (on 1/19/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
EDURANT 25 MG TABLET | $41.36 each |